A detailed history of Ra Capital Management, L.P. transactions in Gh Research PLC stock. As of the latest transaction made, Ra Capital Management, L.P. holds 6,686,689 shares of GHRS stock, worth $58 Million. This represents 0.62% of its overall portfolio holdings.

Number of Shares
6,686,689
Previous 6,601,689 1.29%
Holding current value
$58 Million
Previous $77 Million 41.89%
% of portfolio
0.62%
Previous 1.16%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.69 - $12.49 $568,650 - $1.06 Million
85,000 Added 1.29%
6,686,689 $44.7 Million
Q2 2024

Aug 14, 2024

BUY
$10.5 - $14.81 $69.3 Million - $97.8 Million
6,601,689 New
6,601,689 $77 Million
Q1 2024

May 15, 2024

BUY
$5.34 - $11.09 $3.55 Million - $7.37 Million
664,381 Added 11.89%
6,251,714 $66.6 Million
Q4 2023

Feb 14, 2024

BUY
$5.26 - $11.04 $29.4 Million - $61.7 Million
5,587,333 New
5,587,333 $32.4 Million
Q2 2023

Aug 14, 2023

BUY
$7.88 - $12.74 $48,635 - $78,631
6,172 Added 0.11%
5,587,333 $66.3 Million
Q1 2023

May 15, 2023

BUY
$6.02 - $10.92 $4.11 Million - $7.46 Million
682,788 Added 13.94%
5,581,161 $44.6 Million
Q2 2022

Aug 15, 2022

BUY
$8.99 - $19.87 $638,676 - $1.41 Million
71,043 Added 1.47%
4,898,373 $48.9 Million
Q1 2022

May 16, 2022

BUY
$15.48 - $23.98 $30.7 Million - $47.6 Million
1,983,573 Added 69.75%
4,827,330 $88.3 Million
Q4 2021

Feb 14, 2022

SELL
$14.1 - $27.9 $2.4 Million - $4.75 Million
-170,200 Reduced 5.65%
2,843,757 $66.3 Million
Q3 2021

Nov 15, 2021

BUY
$16.51 - $23.68 $577,883 - $828,847
35,002 Added 1.17%
3,013,957 $66.5 Million
Q2 2021

Aug 16, 2021

BUY
$19.25 - $21.73 $57.3 Million - $64.7 Million
2,978,955 New
2,978,955 $64.7 Million

Others Institutions Holding GHRS

About GH Research PLC


  • Ticker GHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,020,800
  • Market Cap $452M
  • Description
  • GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...
More about GHRS
Track This Portfolio

Track Ra Capital Management, L.P. Portfolio

Follow Ra Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ra Capital Management, L.P. with notifications on news.